Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.